Akoya BioSciences, Inc..
AKYA.US | Research and experimental development on natural sciences and engineering
Akoya BioSciences, Inc. is a biotechnology company focused on providing spatial biology solutions to researchers and biopharmaceutical companies. Their core offerings include platforms, reagents, and software that enable the visualization and analysis of cells within their native tissue context. The...Show More
Better Health for All
30
Akoya's core products, including spatial biology solutions and AI-powered diagnostics, are entirely focused on delivering revolutionary health benefits, particularly in cancer diagnosis and treatment. These solutions enhance diagnostic accuracy, reduce errors, improve efficiency, predict immunotherapy response, and enable precision medicine, with partners reporting up to a 90% reduction in diagnosis time and 80% drop in pathologist discordance.
1
The company has no revenue from products with negative health impacts. Akoya maintains an outstanding safety record, aligning with FDA guidelines and ISO-13485 standards, with hardware, software, and reagent components developed under good manufacturing processes (GMP), anticipating possible failures and designing safeguards.
2
The company's technology, such as the NeraCare biomarker assay, has demonstrated the ability to identify 98% of relapses and 100% of cutaneous melanoma-related deaths in early-stage patients, indicating significant reach for vulnerable populations.
3
Akoya's risk-based approach aligns with FDA guidelines and ISO-13485 standards, demonstrating excellent risk transparency.
4
The company's entire business model is oriented towards health improvement, with significant investment in innovation, including collaborations for companion diagnostics and spatial biomarker development.
5
Akoya aims to create robust systems compatible with existing laboratory infrastructure to minimize errors, ensuring consistent results for patients globally, and partners with organizations like the Singapore Translational Cancer Consortium to address health disparities.
6
The company's focus on early disease detection and predictive biomarkers for cancer treatment response demonstrates a strong emphasis on preventative health. Akoya's CLIA-certified labs and involvement in clinical trials, with demonstrated ability to identify patient response to therapies, reflect exceptional ethical frameworks.
7
The company's platforms generate billions of data points from tissue images, indicating excellent data practices.
8
Fair Money & Economic Opportunity
0
No evidence available to assess Akoya BioSciences, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
20
For fiscal year 2024, the CEO's total compensation was $6,433,027, and the median employee compensation was $131,871, resulting in a CEO pay ratio of 49:1.
1
Fair Trade & Ethical Sourcing
0
Akoya Biosciences' 2025 statement outlines its commitment to preventing modern slavery and human trafficking within its organization and supply chains.
1
The company's Code of Conduct mandates compliance with all applicable laws, including those prohibiting modern slavery and human trafficking.
2
Employees and suppliers are required to adhere to the Code of Conduct.
3
Akoya conducts audits of key suppliers on various compliance areas and analyzes ongoing assessments of modern slavery and human trafficking risks.
4
However, the provided information lacks specific quantitative data for any of the Fair Trade & Ethical Sourcing KPIs, such as fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk, or supplier diversity spend.
5
Honest & Fair Business
-40
Akoya BioSciences has a whistleblower policy that includes a confidential and anonymous financial concern hotline, as required by the SEC.
1
However, there is no evidence provided regarding independent investigation processes, training frequency, or resolution metrics for this policy.
2
Kind to Animals
-40
Akoya Biosciences conducts pre-clinical studies on animals to assess product safety and is categorized as having 'Significant Involvement' in 'Animal Testing'.
1
The company explicitly states this in a cited report.
2
There is no information provided regarding any policy for reduction, prohibition of discretionary testing, or high-level sign-off for exceptions, nor any transparent reduction targets or volume data for animal testing.
3
No War, No Weapons
0
No specific, concrete evidence was found in the provided articles to assess Akoya BioSciences, Inc. against any of the defined KPIs for the 'No War, No Weapons' ethical value.
1
Information regarding other companies (e.g., Hologic) was present but is not applicable to Akoya BioSciences, Inc.
2
Planet-Friendly Business
0
The provided articles do not contain specific, quantifiable evidence for any of the KPIs related to Planet-Friendly Business. While some articles mention general environmental precautions for product handling and disposal, and one notes the use of e-Consent to reduce paper waste, these do not map to the quantitative thresholds of the rubric's KPIs.
1
Information regarding emissions, renewable energy, water use, waste diversion, green building certifications, climate targets, supply chain transparency, or environmental impact assessments is not present.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles to assess Akoya BioSciences, Inc. against the defined Key Performance Indicators for the ethical value "Respect for Cultures & Communities." While the company has a Code of Conduct
1
and employee training programs,
2
the evidence does not explicitly link these to community-specific concerns or cultural sensitivity as required by the KPIs. Information about general grievance mechanisms
3
and employee training on the Code of Conduct was present,
4
but it did not explicitly relate to community concerns or cultural sensitivity as required by the KPIs.
Safe & Smart Tech
10
Akoya has attained SOC 2 Type II attestation, and its ABS laboratory is CLIA certified.
1
The company also received ISO 13485:2016 certification on October 13, 2020, covering the design, development, production, distribution, and installation of medical devices and related services.
2
Akoya team members receive regular training in proper cyber hygiene, and development teams are regularly trained and updated on DevSecOps practices.
3
All data traversing Akoya's platform is encrypted in transit using industry-standard algorithms like TLS and AES.
4
Encryption at rest is not required as the company states it does not store personal customer data.
5
Akoya maintains a framework for identifying, investigating, containing, reporting, mitigating, and minimizing the impact of potential security incidents, and states it is constantly improving security protocols.
6
Akoya adheres to industry standards for systems and infrastructure to ensure data is protected and has incorporated defense-in-depth in its data security and privacy strategy.
7
The company's security program and network are evaluated by financial institutions, independent penetration testers, and audit firms.
8
Akoya explicitly states it does not store personal customer data, adhering to data minimization principles.
9
The company adheres to NIST Cyber Security Framework (CSF), CIS Critical Security Controls, COSO Framework, and other laws, rules, and regulations.
10
Akoya aims to empower consumers to better control their data privacy and security.
11
The platform is built on a Zero Trust security framework, requiring all users to be authenticated, authorized, and continuously validated, and incorporates role-based access control (RBAC) and a least-privilege access model.
12
Zero Waste & Sustainable Products
-10
The company manages hazardous and biological waste products, adhering to federal, state, and local laws and regulations for their use, generation, manufacture, storage, handling, and disposal.
1
Akoya BioSciences has not been subject to any enforcement actions related to waste disposal.
2